A Multi-pronged Therapeutic Strategy
Chromosomal instability (CIN) is one of cancer’s most targetable vulnerabilities. Our understanding of the underlying biological mechanisms of CIN has revealed processes within CIN-high cancer cells previously under-appreciated in oncology drug discovery. Volastra is progressing a pipeline of owned and partnered programs targeting various CIN related pathways.
We are initially focusing our efforts on two therapeutic approaches: Synthetic lethality and Immune Activation. Our end goal? To stop cancer in its tracks.